Pharmaceutical properties of fluticasone propionate nasal drops: a new formulation.
A variety of corticosteroid delivery systems have been considered for the treatment of nasal polyposis. Safety considerations favour local delivery of the drug to the nasal cavity. No topical delivery system is entirely without problems, however, and formulations must address issues of microbiological quality, drug stability, reproducible drug delivery and adequate drug distribution at site, while also offering environmental and patient acceptability. Fluticasone propionate has been formulated in a new nasal drop preparation. As a highly water-insoluble compound, the active fluticasone propionate requires micronization to an optimal particle size and subsequent dispersion with a surface-active wetting agent. The product is presented in a unit dose low-density polyethylene container, manufactured by a blow-fill-seal process and stored in an aluminium foil overwrap. Micronized active has been used to promote optimal local drug delivery, and excipients have been selected for low irritancy potential and high formulation stability. There is no microbiological risk with fluticasone propionate unit dose nasal drops 400 microg and therefore no need to include a preservative in the preparation. They provide a convenient and effective treatment option for patients with nasal polyposis.
Denyer
S
S
Department of Pharmacy, School of Pharmacy and Biomolecular Sciences, University of Brighton, UK.
D000281:Administration, Intranasal; D000730:Androstadienes / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004349:Drug Packaging / Q000379:methods; D004355:Drug Stability; D000068298:Fluticasone; D006801:Humans; D009298:Nasal Polyps / Q000188:drug therapy
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone